Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases.

Authors :: Berardis D
Rapini G
Olivieri L
Giardini A
Lauretis I
Serroni N
Orsolini L
Fornaro M
Iasevoli F
Trotta S
Cottura P
Vellante F
Alessandrini M
Giannantonio MD
Source :: Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology [Clin Psychopharmacol Neurosci] 2021 Feb 28; Vol. 19 (1), pp. 174-178.
Publication Year :: 2021
Abstract: Cariprazine is a novel antipsychotic drug that exerts partial agonism of dopamine D <subscript>2</subscript> /D <subscript>3</subscript> receptors with preferential binding to the D <subscript>3</subscript> receptor, antagonism of 5HT <subscript>2B</subscript> receptors, and partial agonism of 5HT <subscript>1A</subscript> . Currently, cariprazine has shown clinical efficacy in patients with schizophrenia and with bipolar disorder, as well as adjunctive treatment in patients with Major Depressive Disorder (MDD) and drug-resistant MDD. In the present case series, we report on two patients with treatment-resistant schizophrenia and partial response to clozapine who benefit from combination with cariprazine. The effects of cariprazine combination were remarkable also concerning the adverse metabolic effects of clozapine.

Language :: English
ISSN :: 1738-1088
Volume :: 19
Issue :: 1
Database :: MEDLINE
Journal :: Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
Publication Type :: Report
Accession number :: 33508803
Full Text :: https://doi.org/10.9758/cpn.2021.19.1.174